Catheter Precision Inc.
$ 1.13
-7.38%
14 Apr - close price
- Market Cap 3,284,800 USD
- Current Price $ 1.13
- High / Low $ 1.25 / 1.12
- Stock P/E N/A
- Book Value 2.62
- EPS -15.90
- Next Earning Report 2026-05-13
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.35 %
- ROE -1.92 %
- 52 Week High 15.77
- 52 Week Low 0.85
About
Catheter Precision, Inc. develops and delivers electrophysiology products to provide patients, hospitals, and physicians with technologies and solutions to improve the lives of patients with cardiac arrhythmias in the United States. The company is headquartered in Fort Mill, South Carolina.
Analyst Target Price
$2.00
Quarterly Earnings
| Mar 2026 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-31 | 2025-11-13 | 2025-08-11 | 2025-05-05 | 2025-03-27 | 2024-11-14 | 2024-08-14 | 2024-05-06 | 2024-03-29 | 2023-12-21 | 2023-08-14 | 2023-06-02 |
| Reported EPS | -3.3227 | -1.7 | -5.93 | -0.3585 | -1.3475 | -38.19 | -105.83 | -68.4 | -2.8 | -0.28 | -11.5 | -24.65 |
| Estimated EPS | None | 0.08 | 0.02 | 0.05 | -0.2 | -3.42 | -4.94 | -7.98 | -2.3 | -0.23 | -3.02 | -0.34 |
| Surprise | 0 | -1.78 | -5.95 | -0.4085 | -1.1475 | -34.77 | -100.89 | -60.42 | -0.5 | -0.05 | -8.48 | -24.31 |
| Surprise Percentage | None% | -2225% | -29750% | -817% | -573.75% | -1016.6667% | -2042.3077% | -757.1429% | -21.7391% | -21.7391% | -280.7947% | -7150% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-13 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: VTAK
2026-04-13 12:38:41
Catheter Precision announced that a study on its VIVO imaging system for ventricular procedures has been accepted for publication in EP Europace, a prominent European electrophysiology journal. The study, involving 31 patients, found that VIVO accurately predicts arrhythmogenic substrates for scar-dependent ventricular tachycardia, improving procedural efficiency, especially in non-ischemic cardiomyopathy patients. This clinical evidence further supports VIVO's efficacy and accuracy, with plans for a larger multi-center study underway.
2026-04-08 12:11:39
Catheter Precision (NYSE American: VTAK) will attend the European Heart Rhythm Association (EHRA) conference in Paris from April 12–14, 2026. This marks their first major European event since receiving CE Mark clearance for their LockeT device. The company aims to present new data, engage key opinion leaders, and educate physicians and distributors to expand product use and commercial momentum for LockeT.
2026-04-08 12:00:00
Catheter Precision, Inc. announced its attendance at the annual European Heart Rhythm Association (EHRA) conference in Paris from April 12-14, 2026. The company plans to showcase its LockeT suture retention device, which recently received CE Mark approval, and its VIVO non-invasive 3D imaging system. This conference provides an important opportunity for Catheter Precision to engage with key opinion leaders, educate physicians on its products, and further expand its market presence in Europe.
2026-04-06 12:39:46
Catheter Precision, Inc. announced that data regarding its LockeT suture retention device has been accepted by the Journal of Interventional Cardiac Electrophysiology (JICE). The study confirmed LockeT's safety and efficacy for large-bore venous closure, demonstrating high success rates and low complications in 139 patients. This peer-reviewed validation reinforces the product's benefits for physicians, patients, and hospitals, aligning with Catheter Precision's innovation strategy and expanding market interest.
2026-04-06 11:39:45
Catheter Precision announced that a manuscript detailing a 139-patient study of its LockeT suture retention device has been accepted by the Journal of Interventional Cardiac Electrophysiology (JICE). The study reported high procedural success, rapid hemostasis, early ambulation, and low complication rates for large-bore venous access closure, reinforcing LockeT's feasibility and effectiveness in electrophysiology. This peer-reviewed validation is expected to support the company's commercialization efforts and enhance the perceived value of its medical assets, particularly as it explores strategic options for its electrophysiology business.
2026-04-02 23:39:37
Catheter Precision Inc. is seeking a buyer for its cardiac electrophysiology business, which includes FDA and CE Mark approved products LockeT and VIVO, to focus on its Flyte aviation platform. Despite the cardiac business having a high gross profit margin of 92.31%, the company's market capitalization is low, and its stock has significantly declined. Catheter Precision believes monetizing these assets will unlock value and allow it to be valued as a pure-play aviation business.
